Toronto, Ontario — August 5, 2026 — Leads & Copy — Britannia Life Sciences Inc. (CSE: BLAB) announced its intention to initiate a normal course issuer bid (NCIB) to repurchase up to 8,112,717 of its common shares, representing 5% of its outstanding shares. The buyback program, which aims to enhance long-term shareholder value, is set to commence on August 10, 2026, and will extend for a 12-month period, concluding on August 9, 2027, unless the maximum number of shares is acquired earlier or the company terminates the bid. The company believes the current market price of its common shares may not fully reflect its intrinsic value and business prospects.
The purchases will be conducted through the Canadian Securities Exchange (CSE) or other alternative trading systems. The price paid for each common share will be the prevailing market price on the CSE at the time of purchase, subject to applicable laws. All repurchased shares will be canceled.
Britannia Life Sciences Inc. is a Canadian public company structured as a diversified services and investment platform. It operates as a venture builder within the public market, focusing on originating, founding, capitalizing, and supporting new businesses across various sectors. The company’s strategy involves creating long-term shareholder value through significant equity positions and aiming for defined liquidity outcomes.
The company previously issued a news release regarding the NCIB on May 21, 2026.
Source: Britannia Life Sciences Inc.
